Cargando…
Development of Nephrotic Syndrome after Administration of Sorafenib in a Case of Metastatic Renal Cell Carcinoma
Nephrotic syndrome, after administration of tyrosine kinase inhibitors, is uncommon and not well known. A 62-year-old male, who had experienced a left nephrectomy due to a traffic accident 38 years ago, underwent a partial nephrectomy for right renal cell carcinoma (RCC). Histologically, the tumor w...
Autores principales: | Okuno, Yumiko, Kume, Haruki, Hosoda, Chihiro, Homma, Yukio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189476/ https://www.ncbi.nlm.nih.gov/pubmed/22007236 http://dx.doi.org/10.1155/2011/710216 |
Ejemplares similares
-
Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014) -
Renal Cell Carcinoma with Intraluminal Spread of the Entire Upper Urinary Tract
por: Kakutani, Shigenori, et al.
Publicado: (2013) -
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
por: Matsushita, Hirokazu, et al.
Publicado: (2014) -
Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009) -
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)